KELLY HERSH: Open Payments
NPI 1871668335 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,751 in 76 payments from 14 companies in 2025. Trend: 2023 $1,259 · 2024 $1,214 · 2025 $1,751
Food & beverage: $1,659Education: $92
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 19 | $437 |
| Regeneron Healthcare Solutions, Inc. | 14 | $319 |
| Novartis Pharmaceuticals Corporation | 9 | $194 |
| GlaxoSmithKline, LLC. | 9 | $171 |
| Grifols USA, LLC | 5 | $150 |
| GENZYME CORPORATION | 4 | $115 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $102 |
| CSL Behring | 4 | $69 |
| Genentech USA, Inc. | 3 | $68 |
| X4 Pharmaceuticals, Inc. | 1 | $31 |
Products named: DUPIXENT, BREZTRI, XOLAIR, TRELEGY ELLIPTA, TEZSPIRE, FASENRA, Xembify, NEFFY.
Industry payments across CO — which companies pay providers there.
